Pharmacology

Akston Biosciences Corporation partnered with Purdue University to develop a drug targeting PD-L1 in dogs with solid tumors.

Zoetis' relfovetmab product is a long-acting anti–nerve growth factor monoclonal therapy for cats.

The 2 drugs from Elanco now offer protection from emerging tick species and aid in the prevention of Lyme disease in canines.

Zoetis' drug was recently approved in Canada and recommended in Europe.

A doctorate student at UC Davis is receiving up to $10,000 in funding to support their research efforts.

A West Virginia veterinarian faces nearly $1 million in penalties for failing to account for controlled substances and allegedly falsifying records.

Updates on a new vaccine to help protect koalas from chlamydia, and a virtual learning environment providing on-demand professional development for species-specific and mixed-practice veterinarians.

The long-lasting injection was first cleared in Australia and New Zealand in 2023.

Zoetis' Dectomax-CA1 is the first drug to receive conditional approval in the US for addressing this type of parasitic infestation.

The revision removes language about fatal vaccine-induced disease from the skin allergy drug's label.

The agency found that Gallant’s data provides reasonable expectation of effectiveness.

Felixvet's Clindamycin Hydrochloride Tablets gain FDA approval, offering a new oral antibiotic option for treating various canine infections.

Generic furosemide is used to help manage heart failure.

Pegasus Laboratories celebrated the grand opening of a larger facility in Pensacola, Florida, with a ribbon-cutting ceremony.

The monoclonal antibody therapy (Portela; Zoetis) is designed to provide relief from pain associated with osteoarthritis.

Elanco Animal Health is pursuing international approvals for a parasite protection therapy and a dermatology drug.

The parasiticide also treats Dermanyssus gallinae, also known as red mites.

The therapy from Boehringer Ingelheim provides protection against porcine circovirus type 2.

Australian start-up Snoretox pitched the injectable therapy during the 2025 KC Animal Health Corridor Summit in Kansas City, Missouri.

Gamrozyne is the first generic version of Zactran, a pioneer product.

Michael W. Dryden, DVM, MS, PhD, DACVM (Parasitology), delivered a keynote address focused on canine heartworm disease on day 2 of the 2025 Fetch dvm360 Conference in Kansas City, Missouri.

The company voluntarily recalled its 2 lots of product due to potential health risks.

Regulatory approval from animal health authorities is still required before the vaccine can be made commercially available.

The JAK inhibitor will be available to veterinarians and dog owners in the United Kingdom by the end of Q3 2025.